Ultromics announced that it raised $55 million in a Series C financing to support its AI-powered heart failure diagnostic platform.
L&G, Allegis Capital and Lightrock co-led the Series C. Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University also joined in. UChicago Medicine’s venture investment vehicle and UPMC Enterprises participated, too.
Oxford, UK-based Ultromics plans to use the funds to continue advancing its AI technology platform. The FDA-cleared, Medicare-reimbursed technology helps clinicians detect HFpEF and cardiac amyloidosis, two forms of heart failure. Now, the company plans to expand across the U.S. to bring the capabilities to hospitals and echo labs with high volumes of at-risk patients.
Additionally, Ultromics plans to expand its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders.
The Ultromics AI platform extracts hidden disease signals from standard echocardiograms to enable earlier, more accurate detection. It achieves this without requiring new hardware or disrupting clinical workflows. The FDA-cleared EchoGo platform supports HFpEF and cardiac amyloidosis diagnosis with scalability across hospitals, clinics and health systems nationwide through Medicare reimbursement.
“The reality is, hospitals already have the data, they just haven’t had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” said Ross Upton, PhD, CEO and Founder, Ultromics. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”
